1,072 results on '"Preskorn, Sheldon H."'
Search Results
2. Discovery of New Transmitter Systems and Hence New Drug Targets
3. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development
4. Life-threatening Rash Due to Lamotrigine and a Failure to Understand Its Pharmacology: How Forensic Detective Work Uses Medical Knowledge and Clinical Pharmacology to Solve Cases.
5. Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists—Daridorexant, Lemborexant, and Suvorexant—Part 2. Principal Drug Metabolizing Enzyme, Drug-Drug Interactions, and Effects of Liver and Renal Impairment on Metabolism
6. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development
7. The Essential Parallels Between Clinical Practice and the Scientific Method
8. Cerebral Anoxia in an 18-year-old Patient Being Treated for Major Depressive Disorder: How Forensic Detective Work Uses Medical Knowledge Including Clinical Pharmacology to Solve Cases.
9. How an Understanding of the Function of the Locus Coeruleus Led to Use of Dexmedetomidine to Treat Agitation in Bipolar Disorder: Example of Rational Development of Psychiatric Medications
10. COVID-19: Protecting the Vulnerable and Opening the Economy
11. How Loading Dose Strategies for Depot Paliperidone Can Go Wrong
12. An Individual With 2 Distinct Nonpathologic Identities
13. Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness
14. How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major Depression.
15. Eight Clinical Cases and the Lessons They Taught
16. Charting and Handling Therapeutic Drug Monitoring Results: How they Differ From Most Laboratory Results
17. Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials
18. QTc, the Multitude of Ways It Is Calculated and Implications for Clinical Practice: A Case Example
19. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
20. Use of Laboratory in Psychiatry
21. Personalized Medicine in the Treatment of a Patient With Obsessive-Compulsive Disorder With Clomipramine.
22. New Approaches in Translational Medicine for Phase I Clinical Trials of CNS Drugs
23. COVID-19: Why Has the Mortality Rate Declined?
24. Two Clinically Important but Underutilized and Misunderstood Tools: Formulas to Estimate Creatinine Clearance and Therapeutic Drug Monitoring
25. Mental Health Care Providers Dealing With Coronavirus Disease 2019 (COVID-19): What Is the Definition of a Case, How Is That Changing, and What Kinds of Tests Are Available?
26. The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy
27. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes
28. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants
29. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics
30. Thoughts on the Value of Case Series in the Literature
31. Can the Publication of Case Series or Case Reports Lead to a Change in Clinical Practice?
32. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations
33. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature)
34. Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature)
35. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations
36. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development
37. Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing
38. Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists—Daridorexant, Lemborexant, and Suvorexant: Part 1: Pharmacokinetic Profiles
39. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder
40. Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be?
41. Longitudinal Course of Adverse Events With Esketamine Nasal Spray
42. Building a Comprehensive Biopsychosocial Database to Identify Underlying Causes of Suicide and Improve Suicide Prevention
43. Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder—Reply
44. Treatment of Agitation in Individuals With Bipolar Disorder or Schizophrenia: Lessons Learned for Clinical Psychiatry and Psychiatric Drug Development
45. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs
46. Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them
47. CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug—Suvorexant as an Example
48. Use of Laboratory Assessments in Psychiatry
49. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes—Tasimelteon as an Example
50. Seven Mechanistically Different Classes of Medications Can Be Used to Treat Insomnia and Related Sleep Disorders.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.